omniture
logo
Search
康诺亚生物医药科技(成都)有限公司
Media Room

Latest News

rss

Keymed Biosciences Announces 2023 Annual Results and Business Updates

* Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-...

2024-03-27 01:16 681

Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration

CHENGDU, China, March 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its ...

2023-03-18 08:00 5217

Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901

CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 0216...

2023-02-23 13:01 1626

Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM

CHENGDU, China, Jan. 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (Stock Code: 02162 HK) is ple...

2023-01-18 09:52 1706

China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer

CHENGDU, China, Sept. 22, 2022 /PRNewswire/ -- Keymed Biosciences (HKEX:02162) announced that the C...

2022-09-22 13:05 1019

Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350

CHENGDU, China, June 10, 2022 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced today that...

2022-06-10 18:42 1819

FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies

CHENGDU, China, April 19, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S....

2022-04-20 10:27 1291

CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States

CHENGDU, China, April 12, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that its new ...

2022-04-12 15:45 504

Keymed Biosciences Releases 2021 Annual Results

CHENGDU, China, March 30, 2022 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX Code: 02162) released ...

2022-03-30 23:41 2212

Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect

CHENGDU, China, March 7, 2022 /PRNewswire/ -- Keymed Biosciences Inc. (2162.HK) is pleased to annou...

2022-03-07 15:57 2265

Keymed Bio Joins Hang Seng Family of Indexes

HONG KONG, Feb. 18, 2022 /PRNewswire/ --  According to the quarterly review results of Hang Seng Fa...

2022-02-18 22:10 6290